Date Filed | Type | Description |
07/28/2023 |
8-K/A
| Quarterly results |
07/24/2023 |
8-K
| Quarterly results |
07/24/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
07/19/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
07/18/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
07/18/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
07/17/2023 |
8-K
| Other Events Interactive Data |
07/10/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
07/10/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
06/29/2023 |
11-K
| Form 11-K - Annual report of employee stock purchase, savings and similar plans: |
06/16/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
06/16/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
06/16/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
06/09/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
05/31/2023 |
4
| Eckert Patricia (Interim CFO) has filed a Form 4 on ENZO BIOCHEM INC
Txns:
| Granted 25,000 options to buy
@ $2.29, valued at
$57.3k
|
|
05/26/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
05/10/2023 |
SC 13D/A
| Radoff Bradley Louis reports a 9.3% stake in Enzo Biochem, Inc. |
05/08/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
05/08/2023 |
8-K
| Other Events Interactive Data |
04/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/24/2023 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
04/13/2023 |
8-K
| Quarterly results |
04/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
03/27/2023 |
SC 13D
| LABORATORY CORP OF AMERICA HOLDINGS reports a 9.8% stake in Enzo Biochem, Inc. |
03/20/2023 |
10-Q
| Quarterly Report for the period ended January 31, 2023 |
03/16/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
03/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
03/14/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/03/2023 |
8-K
| Quarterly results |
|